Suma Krishnan sold $6.6M of KRYS
President, R&D at Krystal Biotech, Inc.. 25,000 shares at an average of $263.21, traded Mar 4, 2026, filed Mar 6, 2026.
Score components
- +20RolePresident
- +25Trade size$6.6M at market
- 0Share of holdings soldSold 1.8% of holdings
- +15Cluster5 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +2.9%, 3m +18.6%, 6m +41.2%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001298711-26-000004, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 4, 2026 | SOpen-market sale Common Stock10b5-1 | -407 | $257.32 | $105k | 1,427,748 | Mar 6, 2026 |
| Mar 4, 2026 | SOpen-market sale Common Stock10b5-1 | -589 | $258.54 | $152k | 1,427,159 | Mar 6, 2026 |
| Mar 4, 2026 | SOpen-market sale Common Stock10b5-1 | -668 | $259.61 | $173k | 1,426,491 | Mar 6, 2026 |
| Mar 4, 2026 | SOpen-market sale Common Stock10b5-1 | -3,667 | $260.37 | $955k | 1,422,824 | Mar 6, 2026 |
| Mar 4, 2026 | SOpen-market sale Common Stock10b5-1 | -2,931 | $261.41 | $766k | 1,419,893 | Mar 6, 2026 |
| Mar 4, 2026 | SOpen-market sale Common Stock10b5-1 | -1,938 | $262.35 | $508k | 1,417,955 | Mar 6, 2026 |
| Mar 4, 2026 | SOpen-market sale Common Stock10b5-1 | -2,248 | $263.58 | $593k | 1,415,707 | Mar 6, 2026 |
| Mar 4, 2026 | SOpen-market sale Common Stock10b5-1 | -4,852 | $264.64 | $1.3M | 1,410,855 | Mar 6, 2026 |
| Mar 4, 2026 | SOpen-market sale Common Stock10b5-1 | -6,000 | $265.16 | $1.6M | 1,404,855 | Mar 6, 2026 |
| Mar 4, 2026 | SOpen-market sale Common Stock10b5-1 | -1,700 | $266.42 | $453k | 1,403,155 | Mar 6, 2026 |
Related signals
Other insiders at Krystal Biotech, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 38Weak | Krystal Biotech, Inc. | Krish S Krishnan President and CEO | $9.0M 25,000 shares | -2% | |
| 33Weak | Krystal Biotech, Inc. | Suma Krishnan President, R&D | $9.0M 25,000 shares | -2% | |
| 50Moderate | KRYSsell Krystal Biotech, Inc. | Dino A Rossi director | $8.2M 25,000 shares | -33% | |
| 15Weak | Krystal Biotech, Inc. | John Charles Thomas EVP, General Counsel | $347k 1,000 shares | -100% | |
| 45Moderate | Krystal Biotech, Inc. | Krish S Krishnan President and CEO | $7.7M 25,000 shares | -2% | |
| 40Moderate | Krystal Biotech, Inc. | Suma Krishnan President, R&D | $7.7M 25,000 shares | -2% | |
| 42Moderate | Krystal Biotech, Inc. | John Charles Thomas EVP, General Counsel | $194k 642 shares | -100% | |
| 45Moderate | Krystal Biotech, Inc. | Krish S Krishnan President and CEO | $6.6M 25,000 shares | -2% | |
| 40Moderate | Krystal Biotech, Inc. | Daniel Janney director | $3.3M 11,803 shares | -14% | |
| 7Weak | Krystal Biotech, Inc. | Kathryn Romano Chief Accounting Officer | $201k 750 shares | -3% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.